Rivastigmine Tartrate Capsule
Product Images NDC 33342-091

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Rivastigmine Tartrate (NDC 33342-091). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1.5mg-60s (1.5mg 60s)

Label for Rivastigmine Tartrate Capsules, USP 1.5 mg, containing 60 capsules. The label states storage instructions and notes the product is manufactured by Macleods Pharmaceuticals Ltd., India, for Macleods Pharma USA, Inc. It includes the NDC 33342-089-09 and barcode information.*

FDA Label Image

3mg-60s (3mg 60s)

Label for Rivastigmine Tartrate Capsules, USP 3 mg by Macleods Pharmaceuticals Limited. The label shows the product strength as 3 mg per capsule and the package contains 60 capsules. It includes storage instructions and manufacturer details for Macleods Pharma USA, Inc., Plainsboro, NJ, and Macleods Pharmaceuticals Ltd., Daman, India.*

FDA Label Image

4.5mg-60s (4.5mg 60s)

Rivastigmine Tartrate Capsules USP 4.5 mg label from Macleods Pharmaceuticals Limited. The label indicates a package of 60 capsules with dosage strength of 4.5 mg. It includes storage instructions, manufacturer details, an NDC number (33342-091-09), and barcode.*

FDA Label Image

6mg-60s (6mg 60s)

Label for Rivastigmine Tartrate Capsules, USP 6 mg by Macleods Pharmaceuticals Limited. The label shows the product strength of 6 mg per capsule and contains 60 capsules. It is manufactured for Macleods Pharma USA, Inc. The label includes storage instructions and mentions the product is Rx only. Barcodes and regulatory information are also present.*

FDA Label Image

Carton-1.5-mg-100s (Rivastigmine Carton 1.5 mg 100s)

Rivastigmine Tartrate Capsules, USP 1.5 mg oral capsules packaging label showing 100 capsules (10 x 10 unit-dose capsules). Label includes manufacturer Macleods Pharmaceuticals Limited, batch and expiration date fields, storage instructions (20° to 25°C), and a note that the blister pack is not child resistant. Also states each capsule contains 1.5 mg Rivastigmine Tartrate equivalent to Rivastigmine USP.*

FDA Label Image

Carton-1.5-mg-30s (Rivastigmine Carton 1.5 mg 30s)

Rivastigmine Tartrate Capsules, USP 1.5 mg oral capsules label from Macleods Pharmaceuticals Limited. The package contains 30 capsules (3 x 10 unit-dose capsules). The label includes dosage strength prominently displayed several times and the NDC number 33342-089-06.*

FDA Label Image

Carton-3-mg-100s (Rivastigmine Carton 3 mg 100s)

Packaging label for Rivastigmine Tartrate Capsules USP, 3 mg strength, oral capsules. The label shows a package containing 100 capsules (10 x 10 unit-dose capsules). Manufactured by Macleods Pharmaceuticals Limited in India and Macleods Pharma USA, Inc. storage instructions and a note that the blister pack is not child resistant are also included.*

FDA Label Image

Carton-3-mg-30s (Rivastigmine Carton 3 mg 30s)

Rivastigmine Tartrate Capsules, USP 3 mg package label from Macleods Pharmaceuticals Limited. The label indicates the product contains 30 capsules in 3 unit-dose strips of 10 each. The label displays the strength '3 mg' prominently and includes the NDC number 33342-090-06 along with storage and manufacturer information.*

FDA Label Image

Carton-4.5-mg-100s (Rivastigmine Carton 4.5 mg 100s)

Label for Rivastigmine Tartrate Capsules USP, 4.5 mg strength, oral capsule form. The label indicates a package containing 100 capsules in 10 x 10 unit-dose format. It is manufactured by Macleods Pharmaceuticals Limited for Macleods Pharma USA, Inc. Storage instructions and dosage information references are included. The label also notes this blister pack is not child resistant.*

FDA Label Image

Carton-4.5-mg-30s (Rivastigmine Carton 4.5 mg 30s)

Packaging label for Rivastigmine Tartrate Capsules, USP, 4.5 mg strength. The label shows the product name, strength, unit-dose capsule form, and a count of 30 capsules (3 x 10 unit-dose capsules). The labeler is Macleods Pharmaceuticals Limited. The label includes an NDC number 33342-091-06 and dosage details, with a blue and white color scheme.*

FDA Label Image

Carton-6-mg-100s (Rivastigmine Carton 6 mg 100s)

Label for Rivastigmine Tartrate Capsules, USP 6 mg, an oral prescription drug by Macleods Pharmaceuticals Limited. The packaging shows 100 capsules (10 x 10 unit-dose capsules) with storage instructions and manufacturer details including Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Limited, India. The label includes dosage and administration reference and batch/expiration placeholders.*

FDA Label Image

Carton-6-mg-30s (Rivastigmine Carton 6 mg 30s)

Rivastigmine Tartrate Capsules, USP 6 mg oral capsules packaging label. The label shows a quantity of 30 capsules arranged as three 10-unit-dose blister packs. The labeler is Macleods Pharmaceuticals Limited, and the NDC number is 33342-092-06. The label features dosage strength prominently with the product name and manufacturer details.*

FDA Label Image

Figure-1 (Rivastigmine Figure 1)

A line graph illustrating mean change from baseline in ADAS-cog rating over weeks during treatment with rivastigmine tartrate capsules. The graph compares clinical improvement and decline for three groups: 6-12 mg, 1-4 mg, and placebo, with time points at 0, 12, 18, and 26 weeks. Error bars denote SEM.*

FDA Label Image

Figure-2 (Rivastigmine Figure 2)

A cumulative percentage plot showing patients' change from baseline with three treatment groups: 6-12 mg, 1-4 mg, and placebo. The x-axis represents change from baseline, and the y-axis shows cumulative percentage of patients. Vertical lines indicate 7-point, 4-point improvements, and no change thresholds. An inset table summarizes percentage of patients achieving specified improvements in ADAS-cog scores across treatment groups.*

FDA Label Image

Figure-3 (Rivastigmine Figure 3)

A bar chart depicting the percentage of patients by CIBIC-Plus rating across three groups: Placebo, 1-4 mg, and 6-12 mg doses. Ratings range from Markedly Improved to Markedly Worse, showing most patients categorized as Unchanged, with smaller percentages in other categories.*

FDA Label Image

Figure-4 (Rivastigmine Figure 4)

A line graph depicting the mean change from baseline in ADAS-Cog ratings over 26 weeks of treatment. The graph compares clinical improvement and decline among three groups receiving 6-12 mg, 1-4 mg doses of a drug, and placebo. The 6-12 mg group shows noticeable clinical improvement around week 12, while the placebo and 1-4 mg groups trend towards clinical decline.*

FDA Label Image

Figure-5 (Rivastigmine Figure 5)

A cumulative percentage plot showing the change from baseline in ADAS-cog scores for three groups: 6-12 mg, 1-4 mg, and placebo. The x-axis represents change from baseline, with annotations for 7 points, 4 points, and no change; the y-axis shows cumulative percentage of patients. A table presents treatment group ADAS-cog change values at -7, -4, and 0 points.*

FDA Label Image

Figure-6 (Rivastigmine Figure 6)

A bar graph showing the percentage of patients categorized by CIBIC-Plus Rating for placebo, 1-4 mg, and 6-12 mg dosage groups of rivastigmine tartrate. The categories range from Markedly Improved to Markedly Worse, illustrating patient response distribution across treatment groups.*

FDA Label Image

Figure-7 (Rivastigmine Figure 7)

A line graph showing mean change from baseline ADAS-cog rating over 24 weeks during treatment with Rivastigmine versus placebo. The vertical axis represents mean change with error bars (SEM), ranging from clinical decline to clinical improvement. The horizontal axis shows time in weeks (0, 8, 16, 24). Rivastigmine shows increased clinical improvement over time compared to placebo.*

FDA Label Image

Figure-8 (Rivastigmine Figure 8)

Bar chart comparing the percentage of patients across ADCS-CGIC rating categories for Rivastigmine and Placebo groups. The ratings range from Markedly Improved to Markedly Worse, showing varying patient outcome distributions between the two groups.*

FDA Label Image

Structure (Rivastigmine Structure)

Chemical structure of rivastigmine tartrate, showing the molecular arrangement including aromatic ring, ester and amine groups, and the tartrate component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.